Literature DB >> 10465321

Changing patterns of coronary heart disease in the hunter region of New South Wales, Australia.

A J Dobson1, P McElduff, R Heller, H Alexander, P Colley, K D'Este.   

Abstract

A population-based observational study of men and women aged 35-69 years in the Hunter Region of New South Wales, Australia, was conducted to assess the impact of risk-factor modification and increased drug therapy on the trends in major coronary events and case fatality. From 1985 to 1993, there were 3006 coronary deaths and 6450 nonfatal major coronary events. Rates of death and nonfatal myocardial infarction declined, but there was an increase in hospital admissions for prolonged chest pain. Reductions in cigarette smoking, diastolic blood pressure, total cholesterol, and increased use of aspirin can fully explain the 3.3% (95% confidence interval [CI] 2.4, 4.2) average annual reduction in rates of major coronary events for men and the 4.1% (95% CI 2.7, 5.5) reduction for women. In contrast, increased use of aspirin, beta-blockers, fibrinolytic therapy, and angiotensin-converting enzyme inhibitors explain less than half of the 8.9% (95% CI 5.9, 11.8) and 6.9% (95% CI 2.7, 10.9) average annual reduction in case fatality in hospital for men and women, respectively. These trends suggest a decline in severity of coronary heart disease consistent with reductions in risk-factor levels and improved acute medical treatment.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10465321     DOI: 10.1016/s0895-4356(99)00052-9

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  2 in total

Review 1.  Pharmacogenetics of response to statins: where do we stand?

Authors:  Anke-Hilse Maitland-van der Zee; Eric Boerwinkle
Journal:  Curr Atheroscler Rep       Date:  2005-05       Impact factor: 5.113

2.  Trends in incidence, case-fatality and recurrence of myocardial infarction in the Danish MONICA population 1982-1991.

Authors:  M Davidsen; H Brønnum-Hansen; T Jørgensen; M Madsen; L U Gerdes; M Osler; M Schroll
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.